Dr. Wabnitz has extensive experience in clinical development with a unique combination of clinical medicine, pharmacology, toxicology, and industry drug development experience. He has acted as an investigator and Medical Monitor on over 50 first in human Phase I/II clinical trials over the last two years, including several Phase I/II first in human oncology studies, as well as previously being the Executive Medical Director of a leading Australian Phase I clinical unit. His scientific background includes a Ph.D. in Organic Chemistry, a Post Doc at Parke-Davis (Ann Arbor, MI), 6.5 years of drug development industry experience (Pfizer/Esperion), an M.B.A. from the Stephen Ross School of Business (University of Ann Arbor, MI), and a Drug Development certificate in Regulatory Affairs from Temple University (Philadelphia, PA). His clinical background includes a Doctor of Medicine (M.D.), and he is a qualified Specialist Physician and Clinical Pharmacologist (Fellow of the Royal Australasian College of Physician, Australia).
Dr. Mak Jawadekar is currently an independent Pharma Professional. He worked at
Pfizer, Inc. based in Groton-New London Connecticut for 28 consecutive years. In 2010,
he was a Director, Portfolio Management at Pfizer Inc. During his career at Pfizer, he was
responsible for Drug Delivery Technology Assessment function involving external ‘Drug
Delivery’ technologies. He has extensive experience in creating and cultivating external
partnerships and alliances for Drug Delivery Technologies. He began his professional
career at Pfizer Central Research in early 1982, after having completed his Ph.D. in
Pharmaceutics, under Prof. Ed Rippie at the University of Minnesota.
His 28+ years of experience with Pfizer Global R&D specifically includes Solids R&D,
Drug Product formulation/ Dosage Form/ Drug Delivery development, Clinical Trials
Supply Manufacturing, Scale-up and Technology Transfer & Research Pharmacy
functions. He helped create various Pharma R&D Partnerships, JVs, and Collaborations.
He managed several functions/groups within R&D for many years. As a bench Scientist,
he worked on many challenging commercial formulations which became multibillion-
dollar products for many years for Pfizer Inc. These R & D formulations & Product
development programs included ZOLOFT, ZITHROMAX, VIAGRA faster onset,
DIFLUCAN ODT and EXUBERA pulmonary delivery system. He also worked on many
“Life Cycle Management “projects for Pfizer’s existing products. Post Pfizer career, he
worked with KKR, a Private Equity group in New York, for acquisition of Capsugel
division from Pfizer which Pfizer divested later in 2011. Mak has presented at many
professional meetings and has participated in various Panel Discussions/Round Tables
around the globe.
During February 2018, he worked with Mr. Tonino Lamborghini, Chairman, Tonino
Lamborghini S.p.A. from Italy in creating Strategic Collaborations in India, working
through India’s Prime Minister Narendra Modi and the Chief Minister, D. Phadanavis.
Currently, he serves on various company Strategic & Scientific Advisory Boards
around the globe. Some of the list includes:
- Actinium Pharma, New York city
- Applied DNA Technologies, Stony Brook, NY
- Applied Materials Inc., Santa Clara, California
- Tonino Lamborghini SpA, Italy.
- NMBT, Albert Einstein College of Medicine, New York
- Sonnet Bio Therapeutics Inc., Cranbury, NJ
- Saama Technologies Inc., Campbell, California
Serving on the Board of Directors: (Public Companies)
- Preveceutical Medical Inc., Vancouver, Canada
- Cardax Pharma, Honolulu, Hawaii
- Nanoviricides Inc. Shelton, Connecticut
Member of the Board of Directors at a NY based, Non-Profit organization,
- Abilities Inc.
Dr. Hall is widely regarded as a leading researcher in the field of breast cancer and prevention. He is the Head of the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet. Dr. Hall is leading the unique KARMA (Karolinska Mammography Project for Risk Prediction of Breast Cancer) Cohort, including over 70,000 women, which is regarded as the best characterized breast cancer cohort in the world and serves as a resource for studies about breast cancer risk assessment and prevention, and the Karisma Intervention Study, which is studying the change in MBD in women taking various doses of oral tamoxifen.
Dr. Novina is one of the leading researchers in the field of RNAi therapeutics. He is an Associate Professor of Medicine at the Dana-Farber Cancer Institute and Harvard Medical School and an Associate Member of the Broad Institute of Harvard and MIT. He is currently the Principal Investigator of the Novina Lab at the Dana-Farber Cancer Institute. His laboratory has made several important discoveries into the biology of noncoding RNAs, their dysregulation in cancers, and their development as biomedical tools.
Dr. Novina received his M.D. from Columbia University, College of Physicians and Surgeons in 2000 and his Ph.D. from Tufts University, Sackler School of Graduate Biomedical Sciences in 1998. His graduate work has resulted in 10 publications examining transcriptional regulation of TATA-less promoters. In 2014 he received the coveted National Institutes of Health Pioneer Award, which funds bold and innovative research proposals to attack challenging biomedical problems. Dr. Novina has established many collaborations between industry partners and physicians to facilitate his goal of bringing biomedical innovations from bench to bedside.